CDK7 and colitis: In summary, as a prospective inhibitor of CDK7, THZ2 can alleviate the inflammatory symptoms, both in DSS-induced acute colitis and AOM/DSS-induced colorectal cancer mouse models, inhibiting colitis and tumor cell proliferation.